CDK4 and neoplasm: To identify molecular changes induced by CDK4/6 inhibitors, we performed gene expression analyses in baseline, day 15, and surgery tumor samples of patients treated with ribociclib plus letrozole in the CORALLEEN trial (Fig. 3A) as well as in baseline, day 15, and surgery samples of patients treated with palbociclib plus anastrazole in the NeoPalAna trial (Fig. 3B).